TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06206603

Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal biopsies
Description: Approximately 6 biopsies (each around 2-3mm in size) are taken from the polyp or cancer, as well as adjacent healthy intestinal mucosa, during a scheduled colonoscopy. For healthy controls, around 6 biopsies are taken from the healthy intestinal mucosa. The intestinal biopsies are frozen at -80 degrees Celsius.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal biopsies
Description: Approximately 6 biopsies (each around 2-3mm in size) are taken from the polyp or cancer, as well as adjacent healthy intestinal mucosa, during a scheduled colonoscopy. For healthy controls, around 6 biopsies are taken from the healthy intestinal mucosa. The intestinal biopsies are frozen at -80 degrees Celsius.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal biopsies
Description: Approximately 6 biopsies (each around 2-3mm in size) are taken from the polyp or cancer, as well as adjacent healthy intestinal mucosa, during a scheduled colonoscopy. For healthy controls, around 6 biopsies are taken from the healthy intestinal mucosa. The intestinal biopsies are frozen at -80 degrees Celsius.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: A venous blood sample (10ml) will be taken in connection with the colonoscopy. Patients typically receive an intravenous needle for the administration of sedatives and pain-relieving medications during the colonoscopy, so the current blood sample does not cause any additional needle sticks or discomfort for the patient. The blood sample is centrifuged, and the plasma is frozen at -80 degrees Celsius.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: A venous blood sample (10ml) will be taken in connection with the colonoscopy. Patients typically receive an intravenous needle for the administration of sedatives and pain-relieving medications during the colonoscopy, so the current blood sample does not cause any additional needle sticks or discomfort for the patient. The blood sample is centrifuged, and the plasma is frozen at -80 degrees Celsius.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: A venous blood sample (10ml) will be taken in connection with the colonoscopy. Patients typically receive an intravenous needle for the administration of sedatives and pain-relieving medications during the colonoscopy, so the current blood sample does not cause any additional needle sticks or discomfort for the patient. The blood sample is centrifuged, and the plasma is frozen at -80 degrees Celsius.
Study: NCT04882917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4076
Description: M4076 will be administered orally, in Part 1A and Part 1B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4076
Description: M4076 will be administered orally, in Part 1A and Part 1B.
Study: NCT06166784

Intervention type: DEVICE
Intervention: Mectascrew B
Description: reconstruction of ACL or PCL rupture
Study: NCT04970342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (0%/ THC / 0% CBD)
Description: Cannabis vapor is produced from 500 mg of dried plant material (0% THC / 0% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose at two of the three study visits.
Study: NCT06174636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of abdominal weight
Description: Application of variable weight on the abdomen to reach a 5 mmHg increase in IAP
Study: NCT06328985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube feeding
Description: The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
Study: NCT06263556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises
Description: Patients will be informed about pelvic floor muscles functions and written material will be given for home training.~Exercise program will be planned as 1 set, 3 times per day. Each set will include 10 pelvic floor contractions. Patient will be instructed to squeeze their pelvic muscles and keep them contracted for 8 seconds. Due to fatigue and spasticity patients may experience, patients will set their own resting periods between contractions. Patients will be told to avoid contracting abdominal and gluteal muscles and avoid holding their breathe during the exercise.~Patients will be instructed to perform exercise as following:~1. Lie on your back. Take a deep breathe. Relax your abdominal muscles as you breathe out.~2. Focus on your pelvic floor muscles. Squeeze your muscles as you are trying to stop the flow of your urine and stay contracted for 8 seconds, then relax.~3. Repeat when you feel ready. You need to repeat this 10 times.~4. Repeat this exercise 3 times per day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation
Description: Patients in TTSN group will receive posterior tibial nerve stimulation based on the protocol explained before.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Patients in sham stimulation group will receive sham stimulation based on the protocol explained before.
Study: NCT04798755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Inicial dose 15mg/week increasing up to 25 mg/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: At the Baselin visit adalimumab 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.
Study: NCT05174065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study: NCT05250141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa 250mg and Carbidopa 25mg Test Drug tablet
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa 250mg and Carbidopa 25mg Referent Product tablet
Description: Sinemet (Savio Industrial S.R.L, Brazil)
Study: NCT05093972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulonivirine
Description: Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulonivirine
Description: Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulonivirine
Description: Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.
Study: NCT05209035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Trazodone 50mg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch 50mg
Study: NCT05925582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vestibular based exercise program
Description: this group's participants will involve in vestibular based exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: calisthenic based exercise program
Description: this group's participants will involve in calisthenic based exercise program
Study: NCT06356571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SC-OBDS
Description: Pharmaceutical form:Solution for SC-OBDS administration-Route of administration:SC-OBDS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Pharmaceutical form:As per local commercial product-Route of administration:Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Pharmaceutical form:As per local commercial product-Route of administration:Oral (as premedication) or IV/oral equivalent (for management of infusion reaction)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pharmaceutical form:As per local commercial product-Route of administration:IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Pharmaceutical form:As per local commercial product-Route of administration:IV
Study: NCT06130683

Intervention type: OTHER
Intervention: Single-cell sequencing
Description: Single-cell sequencing technology can reveal the gene structure and gene expression status of individual cells, reflecting the heterogeneity between cells.

Intervention type: OTHER
Intervention: Single-cell sequencing
Description: Single-cell sequencing technology can reveal the gene structure and gene expression status of individual cells, reflecting the heterogeneity between cells.

Intervention type: OTHER
Intervention: Single-cell sequencing
Description: Single-cell sequencing technology can reveal the gene structure and gene expression status of individual cells, reflecting the heterogeneity between cells.
Study: NCT06211712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Human Urinary Kallidinogenase
Description: Before the first day of endovascular therapy (non-bridging), dissolve Human Urinary Kallidinogenase in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: Before the first day of endovascular therapy (non-bridging), dissolve placebo in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.
Study: NCT04798755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab+Methotrexate
Description: Adalimumab: at the Baseline visit 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.~Methotrexate:Inicial dose 15mg/week increasing up to 25 mg/week
Study: NCT05944822

Intervention type: OTHER
Intervention: pro-inflammatory cytokines
Description: compare the levels of pro-inflammatory cytokines in patients with Essure® contraceptive implants and in control patients with endometriosis or adenomyosis.

Intervention type: OTHER
Intervention: pro-inflammatory cytokines
Description: compare the levels of pro-inflammatory cytokines in patients with Essure® contraceptive implants and in control patients with endometriosis or adenomyosis.

Intervention type: OTHER
Intervention: pro-inflammatory cytokines
Description: compare the levels of pro-inflammatory cytokines in patients with Essure® contraceptive implants and in control patients with endometriosis or adenomyosis.
Study: NCT05857813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program for the Education and Enrichment of Relational Skills (PEERS®)
Description: developed at the University of California, Los Angeles (E. A. Laugeson \& F. Frankel, 2010). This is a parent-assisted, manualized social skills training program that addresses crucial areas of social functioning for adolescents. Psycho-education and cognitive-behavioral therapy techniques are employed to help adolescents develop ecologically valid skills for making and maintaining friendships.
Study: NCT05342168

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Using a swallowed expanding sponge (Cytosponge TM) to obtain sampling of the esophageal musosa
Description: A gelatin capsule containing the collapsed mesh sponge is swallowed with an attached string fixed to the cheek. After 8 minutes the gelatin capsule will have dissolved and the expanded soft mesh sponge can be with drawn sampling the surface of the esophagus on the way out. The sponge then will be spun and the supernant fixed, processed and stained.
Study: NCT06212141

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisCalor Bulk,VOCO,Germany
Description: It was placed class II restorations.Before applying it, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 15 sec. and Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Then light air pressure will be applied for 5 sec., and then polymerization will be carried out for 10 sec. using LED light.~When it comes to the application of VisCalor , the VisCalor Gun , heating device will be used. A disposable composite capsule will be placed into the device, and it will be heated by selecting program 1 (65°C) for 30 sec. The material will remain hot for 2.5 min.~The nozzle of the capsule on the gun will be directly applied to the deepest part of the cavity, ensuring that the material is placed from bottom to top without exceeding 4 mm. Polymerization will be carried out with LED for 10 sec.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Admira Fusion x-tra,VOCO,Germany
Description: Admira Fusion x-tra composite resin was placed class II restorations. Before applying it an orthophosphoric acid with a concentration of 37% will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 20 sec. And Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec. using LED light with a power of 1200 mW/cm².~Afterwards bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light for 20 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek One Bulk,3M,Germany
Description: Filtek One Bulk composite resin was placed class II restorations. Before applyingthe material, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin, followed by rinsing the cavity with pressurized air and water for 20 sec.Then , adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec using LED light .~Afterwards, bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light at a power of 1200 mW/cm² for 10 sec from all directions, following the manufacturer's recommendations.
Study: NCT06656377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: A total of 25 prediabetic adults of either gender will participate in the study they will engage in exercise at intensities of 50%, 60%, 70%, or 80% of their predicted maximum heart rate (PMHR). In duration they will exercise for 15, 30, 45 and 60 minutes, and in timing protocol they will exercise at various time points after having breakfast. Blood samples were collected at four time points i.e. at fasting, pre-exercise and post-exercise at 30 and 60 minutes to measure glucose, insulin, and C-peptide levels.
Study: NCT05919446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Description: Each session in the ACT group will include the first hour of ACT intervention followed by 1 hour of back exercise class. The ACT group will be led by a trained ACT counsellor and a trained exercise trainer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: back exercise
Description: The control group will undergo 1 hour of back exercise class, while the control group will be led by a trained exercise trainer.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: back exercise
Description: The control group will undergo 1 hour of back exercise class, while the control group will be led by a trained exercise trainer.
Study: NCT06676098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IANBD 3D guided approach
Description: The IANBD will be used to administer the dental anesthetic 2mm medial to the lingula
Study: NCT05992311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: This group will receive the montelukast treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive a placebo pill instead of montelukast
Study: NCT06345495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given by PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Given by Transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given by IV or PO
Study: NCT05276310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-002
Description: IMC-002 blocks the interaction between CD47 and SIRPα.
Study: NCT04567355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Migraine Manager
Description: Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
Study: NCT05908799

Intervention type: DRUG
Intervention: Pembrolizumab + Pemetrexed-Platinum
Description: Medication records in EHR database used to define exposure group

Intervention type: DRUG
Intervention: Pemetrexed-Platinum
Description: Medication records in EHR database used to define comparator group
Study: NCT05377151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Nutrition intervention using either mHealth interventions or conventional methods will be carried out among pregnant women).~Subjects will be allocated into three groups, namely, two interventions group which are:~Group 1: mHealth intervention group (98 subjects)~Group 2: mHealth intervention group + dietitian consultation (98 subjects)~Group 3: control group (98 subjects)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Nutrition intervention using either mHealth interventions or conventional methods will be carried out among pregnant women).~Subjects will be allocated into three groups, namely, two interventions group which are:~Group 1: mHealth intervention group (98 subjects)~Group 2: mHealth intervention group + dietitian consultation (98 subjects)~Group 3: control group (98 subjects)
Study: NCT05573191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The experimental group was injected with lidocaine 1.5mg/kg, and propofol was pumped intravenously at 90s after lidocaine injection.The dose of propofol was further set according to groups. The heart rate, mean arterial pressure, pulse oxygen saturation and NTI values of subjects were recorded in tne basic state,during the 90s after lidocaine administration, 60s after propofol administration and consciousness loss.The control group simply replaced lidocaine with equal volume normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study: NCT06512961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Flossing
Description: Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction Cuff
Description: Inflatable device that exerts an external pressure above a muscle or joint of the extremities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Protocol
Description: The upper limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 15weeks, with 3 training sessions per week, with a day break between sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training Protocol
Description: The upper limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 15weeks, with 3 training sessions per week, with a day break between sessions.